Clinical trial · Interventional
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
NCT05676931CI-TRIAL-00113209EDGE-Lungactive not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel | Drug | Docetaxel | ALIAS |
| Domvanalimab | Drug | — | UNRESOLVED |
| Platinum-Based Doublet | Drug | Platinum Doublet | ALIAS |
| Quemliclustat | Drug | — | UNRESOLVED |
| Zimberelimab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (10)
- type
- EXPERIMENTAL
- label
- A1: Domvanalimab + Zimberelimab
- description
- Domvanalimab and Zimberelimab, both administered by IV infusion
- interventionNames
- Drug: Domvanalimab
- Drug: Zimberelimab
- type
- EXPERIMENTAL
- label
- A2: Domvanalimab + Zimberelimab
- description
- Domvanalimab and Zimberelimab, both administered by IV infusion
- interventionNames
- Drug: Domvanalimab
- Drug: Zimberelimab
- type
- EXPERIMENTAL
- label
- A3: Quemliclustat + Zimberelimab
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically documented Stage IV metastatic, NSCLC * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 * At least one measurable target lesion per RECIST v1.1. * Adequate organ function * Participants must be willing to provide adequate tumor tissue Exclusion Criteria: * Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous * Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s). * Use of supra-physiologic doses of corticosteroids (\> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications ≤ 14 days before the initiation of study treatment (absorbable topical corticosteroids are not excluded). * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.